Ebselen |
SPI-1005; SPI-3005; PZ-51; DR-3305 |
Phase 3 Clinical |
Sound Pharmaceuticals Inc, Daiichi Sankyo Co Ltd |
Tinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders |
Details
|
Olgotrelvir |
STI1558; STI-1558 |
Phase 3 Clinical |
Texas A&M University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
S-892216 |
S-892216 |
Phase 3 Clinical |
Shionogi & Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Mprosevir |
WPV-01 |
Phase 3 Clinical |
Westlake University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
QLS-1128 |
QLS-1128 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
MIR-19 |
MIR-19 |
Phase 3 Clinical |
St. Petersburg Scientific Research Institute of Vaccines and Sera |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Bofutrelvir |
FB-2001; DC-402234 |
Phase 3 Clinical |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Frontier Biotechnologies Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Pomotrelvir |
PBI-0451 |
Phase 2 Clinical |
Pardes Biosciences Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SHEN-211 |
SHEN-211; SHEN211 |
Phase 2 Clinical |
Hubei JKT BioPharma Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
HS-10517 |
HS-10517; HS10517 |
Phase 2 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
EDP-235 |
EDP-235 |
Phase 2 Clinical |
Enanta Pharmaceuticals Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Tollovir |
|
Phase 2 Clinical |
Todos Medical Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Pentarlandir |
SNB-01; SNB-011 |
Phase 2 Clinical |
Syneurx International (Taiwan) Corp |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Nirmatrelvir |
PF-07321332 |
Phase 2 Clinical |
Pfizer As |
Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency |
Details
|
CDI-988 |
CDI988 |
Phase 1 Clinical |
Cocrystal Pharma Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
CMX-990 |
CMX-990; CMX990 |
Phase 1 Clinical |
The Scripps Research Institute Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
WPV-02 |
WPV-02; WPV02 |
Phase 1 Clinical |
Westlake Pharmaceuticals (Hangzhou) Co Ltd |
Virus Diseases |
Details
|
ISM-3312 |
ISM-3312 |
Phase 1 Clinical |
Insilico Medicine Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SYH-2055 |
SYH-2055 |
Phase 1 Clinical |
CSPC Pharmaceutical Group Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Atilotrelvir |
GST-HG171 |
Phase 1 Clinical |
Fujian Guangsheng Zhonglin Biotechnology Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ALG-097558 |
ALG-097558 |
Phase 1 Clinical |
Rega Institute, Ku Leuven, Aligos Therapeutics Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ASC11 |
ASC-11 |
Phase 1 Clinical |
Ascletis Pharma Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Lufotrelvir |
PF-07304814 |
Phase 1 Clinical |
Pfizer Inc |
Coronavirus Disease 2019 (COVID-19); Virus Diseases |
Details
|
Travatrelvir |
TRX-01 |
Clinical |
Traws Pharma Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GS221 |
GS-221; GS221 |
Clinical |
Grand Pharmaceutical (China) Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Ebselen |
SPI-1005; SPI-3005; PZ-51; DR-3305 |
Phase 3 Clinical |
Sound Pharmaceuticals Inc, Daiichi Sankyo Co Ltd |
Tinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders |
Details
|
Olgotrelvir |
STI1558; STI-1558 |
Phase 3 Clinical |
Texas A&M University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
S-892216 |
S-892216 |
Phase 3 Clinical |
Shionogi & Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Mprosevir |
WPV-01 |
Phase 3 Clinical |
Westlake University |
Coronavirus Disease 2019 (COVID-19) |
Details
|
QLS-1128 |
QLS-1128 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
MIR-19 |
MIR-19 |
Phase 3 Clinical |
St. Petersburg Scientific Research Institute of Vaccines and Sera |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Bofutrelvir |
FB-2001; DC-402234 |
Phase 3 Clinical |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Frontier Biotechnologies Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Pomotrelvir |
PBI-0451 |
Phase 2 Clinical |
Pardes Biosciences Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SHEN-211 |
SHEN-211; SHEN211 |
Phase 2 Clinical |
Hubei JKT BioPharma Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
HS-10517 |
HS-10517; HS10517 |
Phase 2 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
EDP-235 |
EDP-235 |
Phase 2 Clinical |
Enanta Pharmaceuticals Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Tollovir |
|
Phase 2 Clinical |
Todos Medical Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Pentarlandir |
SNB-01; SNB-011 |
Phase 2 Clinical |
Syneurx International (Taiwan) Corp |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Nirmatrelvir |
PF-07321332 |
Phase 2 Clinical |
Pfizer As |
Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency |
Details
|
CDI-988 |
CDI988 |
Phase 1 Clinical |
Cocrystal Pharma Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
CMX-990 |
CMX-990; CMX990 |
Phase 1 Clinical |
The Scripps Research Institute Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
WPV-02 |
WPV-02; WPV02 |
Phase 1 Clinical |
Westlake Pharmaceuticals (Hangzhou) Co Ltd |
Virus Diseases |
Details
|
ISM-3312 |
ISM-3312 |
Phase 1 Clinical |
Insilico Medicine Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
SYH-2055 |
SYH-2055 |
Phase 1 Clinical |
CSPC Pharmaceutical Group Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Atilotrelvir |
GST-HG171 |
Phase 1 Clinical |
Fujian Guangsheng Zhonglin Biotechnology Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ALG-097558 |
ALG-097558 |
Phase 1 Clinical |
Rega Institute, Ku Leuven, Aligos Therapeutics Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
ASC11 |
ASC-11 |
Phase 1 Clinical |
Ascletis Pharma Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
Lufotrelvir |
PF-07304814 |
Phase 1 Clinical |
Pfizer Inc |
Coronavirus Disease 2019 (COVID-19); Virus Diseases |
Details
|
Travatrelvir |
TRX-01 |
Clinical |
Traws Pharma Inc |
Coronavirus Disease 2019 (COVID-19) |
Details
|
GS221 |
GS-221; GS221 |
Clinical |
Grand Pharmaceutical (China) Co Ltd |
Coronavirus Disease 2019 (COVID-19) |
Details
|